The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

As the hostilities in the wider Middle East escalate, 7 October 2024 marks one-year since the Hamas-Israel conflict began. Israel's response escalated into conflicts with other organisations, ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Advarra, the market leader in regulatory review solutions and clinical research technology for sites, sponsors, and clinical ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Billionaire investor George Soros became nearly a household name in the early 1990’s by shorting the British pound and making ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...